The top 10 research priorities in bleeding disorders: a James Lind Alliance Priority Setting Partnership

Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P. & Gisselbrecht, C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235–242. Eyre, T.A., Martinez-Calle, N., Hildyard, C., Eyre, D.W., Plaschkes, H., Griffith, J., Wolf, J., Fields, P., Gunawan, A., Oliver, R., Djebbari, F., Booth, S., McMillan, A., Fox, C.P., Bishton, M.J., Collins, G.P. & Hatton, C.S.R. (2019) Impact of intended and relative dose intensity of R-CHOP in a large, consecutive cohort of elderly DLBCL patients: no difference in cumulative incidence of relapse comparing patients by age. Journal of Internal Medicine. https://doi.org/10.1111/joim.12889 M€ uller, C., Murawski, N., Wiesen, M.H.J., Held, G., Poeschel, V., Zeynalova, S., Wenger, M., Nickenig, C., Peter, N., Lengfelder, E., Metzner, B., Rixecker, T., Zwick, C., Pfreundschuh, M. & Reiser, M. (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood, 119, 3276–3284. Peyrade, F., Jardin, F., Thieblemont, C., Thyss, A., Emile, J.F., Castaigne, S., Coiffier, B., Haioun, C., Bologna, S., Fitoussi, O., Lepeu, G., Fruchart, C., Bordessoule, D., Blanc, M., Delarue, R., Janvier, M., Salles, B., Andr e, M., Fournier, M., Gaulard, P. & Tilly, H.; for the Groupe d’Etude des Lymphomes de l’Adulte (GELA) investigators. (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Oncology, 12, 460–468. Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., Bokemeyer, C., Eimermacher, H., Ho, A., Hoffmann, M., Mertelsmann, R., Tr€ umper, L., Balleisen, L., Liersch, R., Metzner, B., Hartmann, F., Glass, B., Poeschel, V., Schmitz, N., Ruebe, C., Feller, A.C. & Loeffler, M.; for the German High-Grade NonHodgkin Lymphoma Study Group (DSHNHL). (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9, 105–116. Pfreundschuh, M., M€ uller, C., Zeynalova, S., Kuhnt, E., Wiesen, M.H.J., Held, G., Rixecker, T., Poeschel, V., Zwick, C., Reiser, M., Schmitz, N. & Murawski, N. (2014a) Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood, 123, 640–646. Pfreundschuh, M., Poeschel, V., Zeynalova, S., H€anel, M., Held, G., Schmitz, N., Viardot, A., Dreyling, M.H., Hallek, M., Mueller, C., Wiesen, M.H.J., Witzens-Harig, M., Truemper, L., Keller, U., Rixecker, T., Zwick, C. & Murawski, N. (2014b) Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group. Journal of Clinical Oncology, 32, 4127– 4133. Pfreundschuh, M., Murawski, N., Zeynalova, S., Ziepert, M., Loeffler, M., H€anel, M., Dierlamm, J., Keller, U., Dreyling, M., Truemper, L., Frickhofen, N., H€ unerlit€ urkoglu, A.N., Schmitz, N., P€ oschel, V., Rixecker, T., Berdel, C., R€ ube, C., Held, G. & Zwick, C. (2017) Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. British Journal of Haematology, 179, 410–420. Smith, A., Crouch, S., Lax, S., Li, J., Painter, D., Howell, D., Patmore, R., Jack, A. & Roman, E. (2015) Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. British Journal of Cancer, 112, 1575– 1584. W€asterlid, T., Mohammadi, M., Smedby, K.E., Glimelius, I., Jerkeman, M., Bottai, M. & Eloranta, S. (2018) Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study. Journal of Internal Medicine. https://doi.org/10.1111/joim.12849